X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ADX-102 (reproxalap) is an investigational new drug candidate, it is a first-in-class small-molecule modulator of RASP, It is being evaluated for the treatment of dry eye disease.
Lead Product(s): Reproxalap
Therapeutic Area: Ophthalmology Product Name: ADX-102
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2024
Details:
ADX-629 is a novel, orally administered RASP (reactive aldehyde species) modulator which is under phase 2 clinical development for the potential treatment of Sjögren-Larsson Syndrome & moderate alcoholic hepatitis.
Lead Product(s): ADX-629
Therapeutic Area: Genetic Disease Product Name: ADX-629
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2024
Details:
ADX-102 (reproxalap) is an investigational new drug candidate, is a first-in-class small-molecule modulator of RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease.
Lead Product(s): Reproxalap
Therapeutic Area: Ophthalmology Product Name: ADX-102
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
Under the option agreement, AbbVie has the option to acquire a co-exclusive license to develop, manufacture, and commercialize ADX-102 (reproxalap), a RASP modulator, in the U.S. and an exclusive license to develop, manufacture, and commercialize reproxalap outside the U.S.
Lead Product(s): Reproxalap
Therapeutic Area: Ophthalmology Product Name: ADX-102
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $501.0 million Upfront Cash: $100.0 million
Deal Type: Licensing Agreement November 01, 2023
Details:
ADX-2191 (methotrexate) is a novel intravitreal formulation of methotrexate, which in preclinical models of retinitis pigmentosa facilitates the clearance of misfolded rhodopsin, a critical visual cycle protein susceptible to genetic mutation.
Lead Product(s): Methotrexate
Therapeutic Area: Genetic Disease Product Name: ADX‑2191
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2023
Details:
ADX‑629 is a novel, orally administered investigational RASP modulator for the potential treatment of systemic and retinal immune-mediated diseases. Currently it is being investigated for chronic cough.
Lead Product(s): ADX‑629
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ADX‑629
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
ADX-2191, a novel formulation of intravitreal injection methotrexate for the potential treatment of proliferative vitreoretinopathy and retinitis pigmentosa.
Lead Product(s): Methotrexate
Therapeutic Area: Oncology Product Name: ADX-2191
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2023
Details:
ADX-102 (reproxalap), an investigational new drug candidate, is a first-in-class small-molecule modulator of RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease.
Lead Product(s): Reproxalap
Therapeutic Area: Ophthalmology Product Name: ADX-102
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2023
Details:
ADX-102 (reproxalap), an investigational new drug candidate, is a first-in-class small-molecule modulator of RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease.
Lead Product(s): Reproxalap
Therapeutic Area: Ophthalmology Product Name: ADX-102
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2023
Details:
ADX-629 is an investigational new drug, is a novel, orally administered RASP (reactive aldehyde species) modulator for the potential treatment of systemic immune-mediated diseases. It s being devloped for the treament for chronic cough .
Lead Product(s): ADX-629
Therapeutic Area: Dermatology Product Name: ADX-629
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
